US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ホーム
投資
株式
アメリカ
NASDAQ
Ascendis Pharma AS (ASND)
Ascendis Pharma AS (ASND) ニュース

Ascendis Pharma AS (ASND)

274.50

6.71

(2.51%)

終了 7月5日 5:00AM

274.50

-0.245

(-0.09%)

取引時間後: 8:59AM

個人投資家向けのプロ仕様のツール。

プレミアム

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

iHub News

iHub News 5月前

BioMarin, Ascendis slide as BridgeBio shakes up achondroplasia landscapeFebruary 12, 2026 10:25 AM
IH Market News
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) and Ascendis Pharma (NASDAQ:ASND) fell roughly 6% after rival BridgeBio Pharma (NASDAQ:BBIO) reported encouraging Phase 3 results for its experimental achondroplasia therapy.BridgeBio said its oral drug infigratinib achieved the primary endpoint in the late-stage PROPEL 3 trial, delivering superior annualized height velocity compared with placebo. The company cited a mean treatment difference of +2.10 cm per year, and noted the therapy also produced the first statistically significant improvement in body proportionality versus placebo in a randomized achondroplasia study.The update is viewed as a potential competitive challenge to BioMarin’s Voxzogo, currently the only treatment for achondroplasia approved by the U.S. Food and Drug Administration.Ascendis, meanwhile, is awaiting a regulatory decision on its once-weekly injectable therapy for achondroplasia, with potential FDA approval expected by February 28. Its shares also retreated following the BridgeBio announcement.Investors appear to be weighing the potential advantages of BridgeBio’s oral formulation, which showed strong efficacy and no serious adverse events linked to the study drug. The company plans to file regulatory submissions in the second half of 2026.Achondroplasia is a rare genetic disorder that affects bone growth, occurring in roughly one in 15,000 to 40,000 births. An estimated 55,000 people across the U.S. and European Union are living with the condition.BioMarin Pharmaceutical stock priceAscendis Pharma stock priceBridgeBio Pharma stock price

Original: BioMarin, Ascendis slide as BridgeBio shakes up achondroplasia landscape

Monksdream

Monksdream 2年前

ASND new 52=week high

Monksdream

Monksdream 2年前

ASND new 52 week high

MiamiGent

MiamiGent 2年前

What goes down, must go up :)
Hope you banked, monk.

Monksdream

Monksdream 2年前

ASND new 52 week high

Monksdream

Monksdream 2年前

ASND new 52 week high

MiamiGent

MiamiGent 3年前

ASND 161 shares traded in pre-mkt. Take your profits- nobody going to hold up this dilution candidate.
Bearish

MiamiGent

MiamiGent 3年前

ASND After just one day of wooing, ASND is FALLING ...........in love with my short.
Irresistible attraction: fourteen-month delay on average, need for more money and a red market with housing assuring further rate increase.
Quote as of 5/02/2023 2:44PM ET
$86.375 -$0.365 (-0.421%)
Bearish
https://www.bing.com/videos/search?q=you+tube+music+roy+orbison+i%27m+falling&view=detail&mid=17436B40AE02F042D00317436B40AE02F042D003&FORM=VIRE

MiamiGent

MiamiGent 3年前

$ASND
A complete response letter (CRL) from the FDA delays a product’s entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them.
FDA NEWS
Bearish

MiamiGent

MiamiGent 3年前

ASND Net Income -$622,419,000 in 2022

Anyone want to venture a guess when the raise will come?

I'll take a WAG and say within two weeks.

MiamiGent

MiamiGent 3年前

ASND Quote as of 5/02/2023 10:14AM ET

$88.07 +$1.33 (+1.533%)

I'm down -3.22% on my short. Did not choose well- 100% owned by institutions.. not easily budged.
I am counting on red days, 3 day rule, CRL and outside chance of a raise- it's all I got, lol

https://stockcharts.com/h-sc/ui?s=ASND

MiamiGent

MiamiGent 3年前

Short today at 85.34

How long will this languish before possible good news?

Will need to raise more $$

crudeoil24

crudeoil24 5年前

Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric Growth Hormone Deficiency > ASND
3:46 pm ET August 25, 2021

By Stephen Nakrosis

Ascendis Pharma A/S on Wednesday said the U.S. Food and Drug Administration approved its Skytrofa as a treatment for Pediatric Growth Hormone Deficiency.

The company said Skytrofa, or lonapegsomatropin-tcgd, is the first once-weekly treatment approved to treat Pediatric Growth Hormone Deficiency.

The company also said Skytrofa was approved to treat "pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone."

The company said the approval includes its Skytrofa Auto-Injector and cartridges, which enable families to store the medicine at room temperature for up to six months.

The company said availability of Skytrofa in the U.S. is expected soon.

Ascendis said it would hold an investor conference call at 4:30 p.m. ET today.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

crudeoil24

crudeoil24 5年前

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Ascendis Pharma AS

Exchange Traded

Corner Growth Acquisition

VanEck Durable High Divi...

Rimbaco Group Global (PK)

Hashdex Nasdaq CME Crypt...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。